New anticoagulants and clinical application of venous thromboembolism

doi:10.3969/j.issn.1004-583X.2016.04.002

Abstract

Abstract: In China, the new anticoagulants, which mainly include two categories: factor Ⅹa inhibitors and factor Ⅱa inhibitors, have been gradually applied in the treatment of venous thromboembolism (VTE). This article illustrates the results of clinical study, application methods and cautions of VTE treatments that employed various new anticoagulants for better clinical using of these drugs and getting best effect of therapy.

Key words: venous thrombosis, anticoagulants, antithrombin Ⅲ, hemorrhage

CLC Number:

R543.6

Yang Yuanhua, Yang Suqiao,Zhang Mingyuan. New anticoagulants and clinical application of venous thromboembolism[J]. Clinical Focus, 2016, 31(4): 352-354.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.04.002

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I4/352

References

[1] Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS)[J]. Eur Heart J, 2014,35(43): 3033-3073.
[2] Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012,141(2 Suppl): e120S-51S.
[3] Bergqvist D. Review of fondaparinux sodium injection for the prevention of venousthromboembolism in patients undergoing surgery[J]. Vasc Health Risk Manag, 2006,2(4): 365-370.
[4] Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism[J]. N Engl J Med, 2003,349(18): 1695-1702.
[5] Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venousthrombosis: a randomized trial[J]. Ann Intern Med,2004,140(11): 867-873.
[6] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363(26): 2499-2510.
[7] Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012,366(14): 1287-1297.
[8] Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism[J]. N Engl J Med, 2013,369(9): 799-808.
[9] Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J]. N Engl J Med, 2013,369(15): 1406-1415.
[10] Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis[J]. Circulation, 2014,129(7): 764-772.
[11] Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism[J]. N Engl J Med, 2013,368(8): 709-718.
[12] Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease[J]. N Engl J Med, 2007,357(11): 1094-1104.
[13] Limone BL, Hernandez AV, Michalak D, et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials[J]. Thromb Res, 2013,132(4): 420-426.
[14] Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace,2013, 15(5): 625-651.
[15] Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study[J]. Clin Pharmacokinet, 2010,49(4): 259-268.
[16] 许欣, 杜军. 急性肺栓塞症的诊治进展[J]. 临床荟萃,2013,28 (6): 699-702.